Glenmark Pharmaceuticals limited
	Unaudited Financial Results for the quarter ended September 30, 2009										(Rs. in Lakhs)
				Standalone						Consolidated
		Quarter ended	Quarter ended	Half year ended	Half year ended	Year ended		Quarter ended	Quarter ended	Half year ended	Half year ended	Year ended
	Particulars	September 30, 2009	September 30, 2008	September 30, 2009	September 30, 2008	March 31, 2009		September 30, 2009	September 30, 2008	September 30, 2009	September 30, 2008	March 31, 2009
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1.	(a)  Net Sales / Income from Operations	23,583.48	22,585.42	45,579.40	41,982.93	85,529.13		59,032.61	55,971.93	113,401.36	102,054.42	209,301.68
	(b)  Other Operating Income	26.23	17.28	40.14	34.54	81.46		1,217.45	120.01	1,722.08	248.46	2,852.25
	(c)  Total Income	23,609.71	22,602.70	45,619.54	42,017.47	85,610.59		60,250.06	56,091.94	115,123.44	102,302.88	212,153.93
2.	Expenditure
	a. (Increase)/Decrease in Stock in Trade and work in process	(1,473.33)	(380.76)	(1,121.90)	(604.11)	(1,516.20)		(4,011.92)	(3,457.03)	165.63	(2,939.05)	(21,117.03)
	b. Consumption of Materials	6,608.38	3,456.50	10,901.37	7,063.36	17,289.71		17,127.72	14,209.79	28,699.01	24,904.06	49,828.52
	c. Purchase of traded goods	1,673.46	1,838.13	2,981.69	3,166.44	6,872.27		5,737.55	5,704.39	7,750.06	7,198.32	37,749.02
	d. Employees Cost	3,271.58	3,047.72	6,032.85	6,623.16	12,983.32		8,813.41	8,199.61	17,020.27	15,486.05	31,227.23
	e. Depreciation	529.86	461.37	1,058.30	893.35	1,910.45		3,624.86	2,252.74	6,740.15	4,405.86	10,268.27
	f. Other expenditure	7,248.96	7,033.24	19,904.65	13,422.19	27,787.96		15,736.45	14,495.00	32,000.61	26,488.44	66,115.56
	g. Total	17,858.91	15,456.20	39,756.96	30,564.39	65,327.51		47,028.07	41,404.50	92,375.73	75,543.68	174,071.57
3.	Profit from Operations before Other Income,	5,750.80	7,146.50	5,862.58	11,453.08	20,283.08		13,221.99	14,687.44	22,747.71	26,759.20	38,082.36
	Interest & Exceptional Items ( 1-2 )
4.	Other Income	261.62	2,534.35	449.32	2,561.34	9,867.77		1,405.65	4,329.20	1,660.26	5,292.43	14,548.91
5.	Profit before Interest & Exceptional Items	6,012.42	9,680.85	6,311.90	14,014.42	30,150.85		14,627.64	19,016.64	24,407.97	32,051.63	52,631.27
	( 3+4 )
6.	Interest ( net )	741.53	1,593.35	939.66	2,542.23	5,513.86		4,561.28	1,870.66	8,945.04	3,422.17	14,047.66
7.	Profit after Interest but before Exceptional Items	5,270.89	8,087.50	5,372.24	11,472.19	24,636.99		10,066.36	17,145.98	15,462.93	28,629.46	38,583.61
	( 5-6 )
8.	Exceptional items	-	-	-	29.80	29.80		-	-	-	-	11,695.48
9.	Profit/(Loss) from Ordinary Activities	5,270.89	8,087.50	5,372.24	11,442.39	24,607.19		10,066.36	17,145.98	15,462.93	28,629.46	26,888.13
	before tax   ( 7-8 )
10.	Tax Expenses	(479.29)	1,398.83	(899.94)	(929.85)	2814.56*		1,977.85	5,409.97	2,028.97	5,355.77	7540.84*
11.	Net Profit/(Loss) from Ordinary Activities	5,750.18	6,688.67	6,272.18	12,372.24	21,792.63		8,088.51	11,736.01	13,433.96	23,273.69	19,347.29
	after tax  ( 9-10 )
12.	Paid-up Equity Share Capital	2,695.81	2,501.95	2,695.81	2,501.95	2,505.20		2,695.81	2,501.95	2,695.81	2,501.95	2,505.20
	(Face value per share Re.1)
13.	Reserves Excluding Revaluation Reserves	-	-	-	-	120,491.85		-	-	-	-	157,310.44
14.	Earning Per Share
	Basic Earnings Per Share (in rupees)	2.27	2.67	2.49	4.96	8.72		3.15	4.69	5.27	9.32	7.74
	Diluted Earnings Per Share (in rupees)	2.26	2.62	2.48	4.85	8.54		3.14	4.59	5.25	9.13	7.58
15.	Public Shareholding
	Number of Shares	139,086,474	119,783,120	139,086,474	119,783,120	120,024,179		139,086,474	119,783,120	139,086,474	119,783,120	120,024,179
	Percentage of Shareholding	51.59%	47.88%	51.59%	47.88%	47.91%		51.59%	47.88%	51.59%	47.88%	47.91%
16.	Promoters and promoter group Shareholding
	a) Pledged/Encumbered
	- Number of shares	Nil	N.A.	Nil	N.A.	Nil		Nil	N.A.	Nil	N.A.	Nil
	- Percentage of shares (as a % of the total shareholding of	Nil	N.A.	Nil	N.A.	Nil		Nil	N.A.	Nil	N.A.	Nil
	promoter and promoter group)
	- Percentage of shares (as a% of the total share capital of the	Nil	N.A.	Nil	N.A.	Nil		Nil	N.A.	Nil	N.A.	Nil
	company)
	b) Non-encumbered
	- Number of Shares	130,494,579	N.A.	130,494,579	N.A.	130,495,579		130,494,579	N.A.	130,494,579	N.A.	130,495,579
	- Percentage of shares (as a% of the total shareholding of	100.00%	N.A.	100.00%	N.A.	100.00%		100.00%	N.A.	100.00%	N.A.	100.00%
	promoter and promoter group)
	- Percentage of shares (as a % of the total share capital of the	48.41%	N.A.	48.41%	N.A.	52.09%		48.41%	N.A.	48.41%	N.A.	52.09%
	company)
* includes Prior Period Tax
Notes:
1	The above results were reviewed by the Audit Committee and approved at the meeting of the Board of Directors held on October 29, 2009.
2	The Statutory Auditors have carried out a limited review of the Standalone result for the quarter and half year ended September 30, 2009.
3	The Company is exclusively in the Pharmaceutical business segment.
4	During the quarter ended September 30, 2009, pursuant to Employee Stock Option Scheme 2003, the Company granted 141,500 options and converted 282,560 options into equity shares of Re. 1 each. As at September 30, 2009, 3,172,100 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
5	In the Standalone result, As per the transitional provision given in the notification issued by Ministry of Corporate Affairs dated March 31, 2009 the Company has opted for the option of adjusting the exchange difference on long term foreign currency monetary items i) To the cost of the assets acquired out of this foreign currency monetary item. During the quarter, company has capitalised exchange difference amounting to Rs. 3.30 lakhs on restatement of long term loans used for acquiring the fixed assets. ii) To the Foreign Currency Monetary Item Translation Difference account. During the quarter, company has transferred exchange loss of Rs. 72.77 lakhs  on restatement of long term loans. Accordingly, proportionate amount of Rs. 172.75 lakhs is amortised for the quarter ended September 30, 2009.Due to the above, profit for the quarter is lower by Rs. 96.68 lakhs.
6	In Standalone result, other expenditure includes Foreign currency exchange loss of Rs. 4,952.81 lakhs for the half year  ended September 30, 2009  (Previous period exchange gain of Rs. 2,206.77 lakhs).
7	The Company has allotted 18,712,935 equity shares of Re 1 each at a premium of Rs. 220/- per share on September 18, 2009 to QIBs pursuant to chapter VIII of the Securities Exchange Board of India (Issue of Capital and Disclosure Requirement ) Regulation 2009. The net funds from the QIP proceeds have since been utilised in full for repayment/ prepayment of debts, in accordance with the terms of the issue.
8	There were no investor complaints pending at the beginning of the quarter. 8 complaints were received from investors during the quarter and same have been resolved.
9	In the Standalone result, for the half year ended 30th September, 2009, Net sales includes export sales Rs. 11,125.92 lakhs (Previous period Rs.12,416.32 lakhs).
10	Diluted EPS includes provision for conversion of FCC Bonds and ESOPs.
11	Previous period's figures have been re-grouped/ re-classified wherever necessary.
										For and on behalf of the Board of Directors
	Mumbai, October 29, 2009									Glenn Saldanha
	Visit us at www.glenmarkpharma.com									Managing Director  &  CEO